SUPN
Supernus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$43.53
−1.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 830.4M | 719.0M | 661.8M | 607.5M | 667.2M |
| Cost of Revenue | 99.0M | 74.6M | 77.9M | 83.8M | 87.2M |
| Gross Profit | 731.4M | 644.4M | 583.9M | 523.7M | 580.0M |
| Operating Expenses | |||||
| R&D Expense | 126.1M | 106.2M | 108.8M | 91.6M | 74.6M |
| SG&A Expense | 560.9M | 485.6M | 335.8M | 336.4M | 377.2M |
| General & Admin Expense | 182.7M | 196.9M | 247.3M | 236.7M | 109.4M |
| Selling & Marketing Expense | 253.0M | 288.7M | 88.5M | 99.7M | 267.8M |
| Other Expenses | 157.1M | 89.5M | 57.7M | 101.1M | 82.1M |
| Total Operating Expenses | 844.1M | 681.3M | 502.2M | 529.0M | 533.9M |
| Cost and Expenses | 942.3M | 755.8M | 580.2M | 612.8M | 621.1M |
| Operating Income (EBIT) | (111.8M) | (36.9M) | 81.7M | (5.3M) | 46.1M |
| Non-Operating | |||||
| Interest Income | 9.3M | 13.3M | 16.2M | 10.5M | 21.7M |
| Interest Expense | 2.3M | — | — | 2.4M | 7.1M |
| Net Interest Income | 7.0M | 13.3M | 16.2M | 8.0M | 14.6M |
| Other Non-Op Income/Expense | (11.7M) | (12.2M) | 16.2M | 8.0M | 14.6M |
| Non-Operating Income (excl Interest) | 5.8M | 12.2M | (16.2M) | (10.5M) | (21.7M) |
| EBT (Pre-Tax Income) | (123.5M) | (49.0M) | 97.9M | 2.8M | 60.7M |
| Income Tax Expense | (13.6M) | (10.5M) | 24.0M | 1.5M | 32.0K |
| Bottom Line | |||||
| Net Income | (109.9M) | (38.5M) | 73.9M | 1.3M | 60.7M |
| Earnings from Cont. Ops | (109.9M) | (38.5M) | 73.9M | 1.3M | 60.7M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (109.9M) | (38.5M) | 73.9M | 1.3M | 64.3M |
| Per Share | |||||
| Basic EPS | ($1.92) | ($0.68) | $1.34 | $0.02 | $1.13 |
| Diluted EPS | ($1.92) | ($0.68) | $1.32 | $0.02 | $1.04 |
| Revenue Per Share | $14.30 | $12.74 | $12.01 | $11.14 | $12.43 |
| Shares | |||||
| Basic Shares Outstanding | 58.1M | 56.5M | 55.1M | 54.5M | 53.7M |
| Diluted Shares Outstanding | 58.1M | 56.5M | 56.0M | 55.5M | 61.7M |
| Profitability Metrics | |||||
| EBITDA | (15.9M) | 42.5M | 178.3M | 90.0M | 153.4M |
| D&A | 101.7M | 91.6M | 80.4M | 84.9M | 85.5M |
| EBIT | (117.6M) | (49.0M) | 97.9M | 5.2M | 67.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026